Tier 4 — mechanistic

Long-Term Nicotinamide Riboside Use Improves Coordination and Eye Movements in Ataxia Telangiectasia

Presterud R, Deng WH, Wennerström AB, Burgers T, Gajera B, Mattsson K, Solberg A, Fang EF, Nieminen AI, Stray-Pedersen A, Nilsen H
Movement disorders : official journal of the Movement Disorder Society 2024 39; 2; 360-369

Bibliography

PubMed
PMID 37899683
DOI
10.1002/mds.29645
Funding
KLINBEFORSK and the University of Oslo Medical Student Research Program; ChromaDex supplied NR.
Competing interests
The publication disclosed ChromaDex product supply.

Study snapshot

DesignOpen-label human intervention study
ModelHuman participants
Sample13 enrolled; 10 completed the 2-year study
InterventionNR escalated from 75 mg twice daily to 250 mg twice daily
Duration2 years; principal neuromotor comparison at 18 months
EndpointsBlood NAD+; neuromotor scales; safety

What the study showed, in plain terms

Coordination and eye-movement measures improved or progressed more slowly than expected from historical data during open-label NR use.

Key findings

Coordination and eye-movement measures improved or progressed more slowly than expected from historical data during open-label NR use.

What this study can and cannot tell us

No randomized placebo comparison; historical-control and developmental effects may influence the findings. This is not proof of broad neuroprotection.

Related papers in the corpus

Tier 4
Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia
Veenhuis SJG et al. · Movement disorders : official journal of the Movement Disorder Society · 2021
Tier 4
Nicotinamide Riboside for Ataxia Telangiectasia: A Report of an Early Treated Individual
Steinbrücker K et al. · Neuropediatrics · 2023
Tier 2
Safety and efficacy of individualised exercise and NAD+ precursor supplementation in patients with Friedreich's ataxia in the USA: a single-centre, 2 × 2 factorial, randomised controlled trial
Lin KY et al. · The Lancet. Neurology · 2026
Tier 4
Effects of nicotinamide riboside in mitochondrial DNA disease
Katherine R. Schon et al. · Genome Medicine · 2026
Tier 2
Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial
Shoji M et al. · Aging cell · 2025
Tier 4
ACAD9 treatment with bezafibrate and nicotinamide riboside temporarily stabilizes cardiomyopathy and lactic acidosis
Van Hove JLK et al. · Mitochondrion · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology